<DOC>
	<DOC>NCT00637728</DOC>
	<brief_summary>Purpose of the study is to compare the effects of megestrol acetate concentrated suspension and placebo on caloric intake for the treatment of cancer-associated anorexia in patients with lung or pancreatic cancer</brief_summary>
	<brief_title>Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Stage II, III,or IV lung or pancreatic cancer Fair, poor, or very poor appetite Cancer associated anorexia/cachexia Weight loss perceived to be associated with diminished appetite Eastern Cooperative Oncology Group Performance score of 0, 1, 2 Life expectancy &gt;3 months Alert and mentally competent Women of childbearing potential required to use an adequate and reliable method of contraception. Postmenopausal women have to have been so for at least 1 year Screening laboratory values must not be clinically significant (some exceptions per protocol) Brain, or head and neck metastases that may interfere with food consumption AIDSrelated wasting Radiation therapy to the head and neck, abdomen, or pelvis within past 6 weeks, or anticipated during course of the study such that the result may interfere with food consumption Conditions that interfere with oral intake, or ability to swallow Absence of a normally functioning gut Mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome Intractable or frequent vomiting that regularly interfere with eating Clinically significant diarrhea History of recurrent thromboembolic events, a thromboembolic event in past 3 months, or longterm anticoagulation treatment for thromboembolism Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism Poorly controlled hypertension, or congestive heart failure Pregnant/lactating females Use within past 30 days of an appetite stimulant Use within past week, or planned use during the study of parenteral nutrition or tube feedings Chronic use of steroids within past 3 months (intermittent shortterm use allowed) Current use of or not willing to abstain from using illicit substances Allergy, hypersensitivity, or contraindication to megestrol acetate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Megestrol acetate</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Unintended weight loss</keyword>
	<keyword>Body weight</keyword>
	<keyword>Appetite</keyword>
	<keyword>Megace ES</keyword>
</DOC>